TY - JOUR
T1 - Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan
T2 - evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis
AU - Naiki, Hironobu
AU - Yamaguchi, Aina
AU - Sekijima, Yoshiki
AU - Ueda, Mitsuharu
AU - Ohashi, Kenichi
AU - Hatakeyama, Kinta
AU - Ikeda, Yoshihiko
AU - Hoshii, Yoshinobu
AU - Shintani-Domoto, Yukako
AU - Miyagawa-Hayashino, Aya
AU - Tsujikawa, Hanako
AU - Endo, Jin
AU - Arai, Tomio
AU - Ando, Yukio
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Background: In 2019, 2020 and 2022, the Japanese Government approved the use of tafamidis and two technetium-scintigraphies for transthyretin amyloid (ATTR) cardiomyopathy, and announced the patient criteria for tafamidis therapy. In 2018, we had started a nation-wide pathology consultation of amyloidosis. Objective: To reveal the impact of approval of tafamidis and technetium-scintigraphy on the diagnosis of ATTR cardiomyopathy. Methods: Ten institutes participated in this study on the pathology consultation of amyloidosis and shared rabbit polyclonal anti-κ116-133, anti-λ118-134, and anti-transthyretin115-124 antibodies. Proteomic analysis was performed when the typing diagnosis by immunohistochemistry was unavailable. Results: Out of 5400 consultation cases received from April 2018 to July 2022, the type of amyloidosis by immunohistochemistry was determined in 4119 of the 4420 Congo-red positive cases. The incidences of AA, ALκ, ALλ, ATTR, Aβ2M and others were 3.2, 11.3, 28.3, 54.9, 0.6 and 1.8%, respectively. Out of 2208 cardiac biopsy cases received, 1503 cases were ATTR positive. There were 4.0 and 4.9 times more total cases and ATTR-positive cases, respectively, in the last 12 months as compared to the first 12 months. Conclusions: The approval of tafamidis and technetium-scintigraphy raised the awareness of ATTR cardiomyopathy, leading to an upsurge in ATTR-positive cardiac biopsy cases.
AB - Background: In 2019, 2020 and 2022, the Japanese Government approved the use of tafamidis and two technetium-scintigraphies for transthyretin amyloid (ATTR) cardiomyopathy, and announced the patient criteria for tafamidis therapy. In 2018, we had started a nation-wide pathology consultation of amyloidosis. Objective: To reveal the impact of approval of tafamidis and technetium-scintigraphy on the diagnosis of ATTR cardiomyopathy. Methods: Ten institutes participated in this study on the pathology consultation of amyloidosis and shared rabbit polyclonal anti-κ116-133, anti-λ118-134, and anti-transthyretin115-124 antibodies. Proteomic analysis was performed when the typing diagnosis by immunohistochemistry was unavailable. Results: Out of 5400 consultation cases received from April 2018 to July 2022, the type of amyloidosis by immunohistochemistry was determined in 4119 of the 4420 Congo-red positive cases. The incidences of AA, ALκ, ALλ, ATTR, Aβ2M and others were 3.2, 11.3, 28.3, 54.9, 0.6 and 1.8%, respectively. Out of 2208 cardiac biopsy cases received, 1503 cases were ATTR positive. There were 4.0 and 4.9 times more total cases and ATTR-positive cases, respectively, in the last 12 months as compared to the first 12 months. Conclusions: The approval of tafamidis and technetium-scintigraphy raised the awareness of ATTR cardiomyopathy, leading to an upsurge in ATTR-positive cardiac biopsy cases.
KW - Cardiac biopsy
KW - immunohistochemistry
KW - tafamidis
KW - technetium-scintigraphy
KW - transthyretin amyloid cardiomyopathy
UR - http://www.scopus.com/inward/record.url?scp=85148503628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148503628&partnerID=8YFLogxK
U2 - 10.1080/13506129.2023.2180334
DO - 10.1080/13506129.2023.2180334
M3 - Article
C2 - 36795075
AN - SCOPUS:85148503628
SN - 1350-6129
VL - 30
SP - 321
EP - 326
JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
IS - 3
ER -